Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'PHASE-II TRIAL' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1912 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wolff, RA
      Novel therapies for pancreatic cancer

      CANCER JOURNAL
    2. Argiris, A; Murren, JR
      Advances in chemotherapy for small cell lung cancer: Single-agent activityof newer agents

      CANCER JOURNAL
    3. Gitlitz, BJ; Hoffman, DMJ; Moldawer, N; Belldegrun, A; Figlin, RA
      Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: An analysis of 124 consecutively treated patients

      CANCER JOURNAL
    4. Steer, C; Harper, P
      Is there any place for cytotoxic chemotherapy in endometrial cancer?

      BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY
    5. Miller, KD; Spooner, K; Herpin, BR; Rock-Kress, D; Metcalf, JA; Davey, RT; Falloon, J; Kovacs, JA; Polis, RA; Walker, RE; Masur, H; Lane, HC
      Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion

      CLINICAL IMMUNOLOGY
    6. Zogakis, TG; Libutti, SK
      General aspects of anti-angiogenesis and cancer therapy

      EXPERT OPINION ON BIOLOGICAL THERAPY
    7. Barry, OP; Kazanietz, MG
      Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy

      CURRENT PHARMACEUTICAL DESIGN
    8. Brandes, AA; Basso, U; Pasetto, LM; Ermani, M
      New strategy developments in brain tumor therapy

      CURRENT PHARMACEUTICAL DESIGN
    9. Jelic, S; Babovic, N; Stamatovic, L; Kreacic, M; Matkovic, S; Popov, I
      Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures - A single-center study

      MEDICAL ONCOLOGY
    10. Harries, M; Kaye, SB
      Recent advances in the treatment of epithelial ovarian cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    11. Fishman, M; Seigne, J; Antonia, S
      Novel therapies for renal cell carcinoma

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    12. Harrington, KJ
      Liposomal cancer chemotherapy: current clinical applications and future prospects

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    13. Tentori, L; Portarena, I; Bonmassar, E; Graziani, G
      Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells

      CELL DEATH AND DIFFERENTIATION
    14. Johnson, PWM
      The therapeutic use of antibodies for malignancy

      TRANSFUSION CLINIQUE ET BIOLOGIQUE
    15. Schuette, W; Bork, I; Wollschlager, B; Schadlich, S
      Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer

      CLINICAL DRUG INVESTIGATION
    16. Jennings, MT; Iyengar, S
      Pharmacotherapy of malignant astrocytomas of children and adults - Currentstrategies and future trends

      CNS DRUGS
    17. Brown, RE; Hutton, J; Burrell, A
      Cost effectiveness of treatment options in advanced breast cancer in the UK

      PHARMACOECONOMICS
    18. Plosker, GL; Hurst, M
      Paclitaxel - A pharmacoeconomic review of its use in non-small cell lung cancer

      PHARMACOECONOMICS
    19. Imam, SK
      Status of radioimmunotherapy in the new millennium

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    20. Friedberg, JW; Neuberg, D; Monson, J; Jallow, H; Nadler, LM; Freedman, AS
      The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    21. Wood, AM
      Rituximab: An innovative therapy for non-Hodgkin's lymphoma

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    22. Shah, MA; Schwartz, GK
      Cell cycle-mediated drug resistance: An emerging concept in cancer therapy

      CLINICAL CANCER RESEARCH
    23. Jung, CP; Motwani, MV; Schwartz, GK
      Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotidereductase M2 subunit

      CLINICAL CANCER RESEARCH
    24. Robinson, BW; Shewach, DS
      Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breastcarcinoma cell lines

      CLINICAL CANCER RESEARCH
    25. Minotti, G; Saponiero, A; Licata, S; Menna, P; Calafiore, AM; Teodori, G; Gianni, L
      Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium

      CLINICAL CANCER RESEARCH
    26. Seraj, MJ; Thomas, AR; Chin, JL; Theodorescu, D
      Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder

      CLINICAL CANCER RESEARCH
    27. Ferguson, WS; Harris, MB; Goorin, AM; Gebhardt, MC; Link, MP; Shochat, SJ; Siegal, GP; Devidas, M; Grier, HE
      Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group trial

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    28. Raney, RB; Anderson, JR; Barr, FG; Donaldson, SS; Pappo, AS; Qualman, SJ; Wiener, ES; Maurer, HM; Crist, WM
      Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for intergroup rhabdomyosarcoma study V

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    29. Cairo, MS; Shen, V; Krailo, MD; Bauer, M; Miser, JS; Sato, JK; Blatt, J; Blazar, BR; Frierdich, S; Liu-Mares, W; Reaman, GH
      Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children withrecurrent or refractory solid tumors: A Children's Cancer Group report

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    30. Kintzel, PE
      Prophylaxis for paclitaxel hypersensitivity reactions

      ANNALS OF PHARMACOTHERAPY
    31. Armstrong, WS; Kazanjian, P
      Use of cytokines in human immunodeficiency virus-infected patients: Colony-stimulating factors, erythropoietin, and interleukin-2

      CLINICAL INFECTIOUS DISEASES
    32. Leong, SS; Tan, EH; Khoo-Tan, HS; Yang, TL; Wee, J; Tan, SH; Poh, WT; Tan, NG
      Recurrent nasopharyngeal carcinoma presenting as diffuse dermal lymphatic infiltration in the neck: Three case reports

      HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
    33. Harrison, D; Sauthoff, H; Heitner, S; Jagirdar, J; Rom, WN; Hay, JG
      Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect

      HUMAN GENE THERAPY
    34. Tinmouth, A; Zanke, B; Imrie, KR
      Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    35. Gregory, SA; Vose, J; Modiano, M; Kraemer, K; Rifkin, R; Rubin, A; Menduni, T; Ghalie, R
      Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin- or mitoxantrone-containing regimen

      LEUKEMIA & LYMPHOMA
    36. Wolff, AC
      Systemic therapy

      CURRENT OPINION IN ONCOLOGY
    37. Godley, PA; Taylor, M
      Renal cell carcinoma

      CURRENT OPINION IN ONCOLOGY
    38. Rini, BI; Small, EJ
      An update on prostate cancer

      CURRENT OPINION IN ONCOLOGY
    39. Weiden, PL; Breitz, HB
      Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL)

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    40. Goldenberg, DM
      The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    41. DeNardo, GL; Juweid, ME; White, CA; Wiseman, GA; DeNardo, SJ
      Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    42. Markman, M
      Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    43. Choy, H
      Taxanes in combined modality therapy for solid tumors

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    44. Flechon, A; Culine, S; Droz, JP
      Intensive and timely chemotherapy, the key of success in testicular cancer

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    45. Kim-James, HY; Heffernan, MP
      The diagnosis, evaluation, and treatment of cutaneous T-cell lymphoma

      CURRENT PROBLEMS IN DERMATOLOGY-US
    46. Bache, M; Oehlmann, S; Meye, A; Bartel, F; Kappler, M; Wurl, P; Schmidt, H; Rath, FW; Dunst, J; Taubert, H
      Radiosensitization in sarcoma cell lines with a p53 missense mutation correlates with prevention of irradiation G2/M arrest but not with induction ofapoptosis

      ONCOLOGY REPORTS
    47. Lauerova, L; Dusek, L; Spurny, V; Simickova, M; Rovny, A; Rejthar, A; Kocak, I; Kovarik, J
      Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients

      ONCOLOGY REPORTS
    48. Adachi, S; Itani, Y; Ito, K; Noda, T; Shintani, M; Saito, K; Furukawa, N; Tomii, Y
      Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer

      ONCOLOGY REPORTS
    49. Danova, M; Porta, C; Ferrari, S; Riccardi, A
      Strategies of medical treatment for metastatic breast cancer

      INTERNATIONAL JOURNAL OF ONCOLOGY
    50. Farmer, JP; Montes, JL; Freeman, CR; Meagher-Villemure, K; Bond, MC; O'Gorman, AM
      Brainstem gliomas - A 10-year institutional review

      PEDIATRIC NEUROSURGERY
    51. Margaritora, S; Cesario, A; Galetta, D; D'Andrilli, A; Macis, G; Mantini, G; Trodella, L; Granone, P
      Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging?

      EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
    52. Lonning, PE
      Exemestane: a review of its clinical efficacy and safety

      BREAST
    53. Davidson, NE; Wolff, AC
      The use of anthracyclines and taxanes for adjuvant therapy of breast cancer

      BREAST
    54. Schmid, P; Possinger, K
      Liposomal anthracyclines for improved cardiac tolerability

      BREAST
    55. Marty, M
      Liposomal doxorubicin (Myocet (TM)) and conventional anthracyclines: a comparison

      BREAST
    56. Kosmas, C; Tsavaris, N; Panopoulos, C; Vadiaka, M; Stavroyianni, N; Kourelis, T; Malamos, N; Antonopoulos, M; Kalofonos, HP
      Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane plus platinum-based regimens

      EUROPEAN JOURNAL OF CANCER
    57. Laack, E; Mende, T; Benk, J; Chemaissani, A; Scholtze, J; Lorenz, C; Niestroy, A; Dalhoff, K; Muller, T; Walter, T; Durk, H; Edler, L; Hossfeld, DK
      Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial

      EUROPEAN JOURNAL OF CANCER
    58. Roovers, RC; van der Linden, E; de Bruine, AP; Arends, JW; Hoogenboom, HR
      Identification of colon tumour-associated antigens by phage antibody selections on primary colorectal carcinoma

      EUROPEAN JOURNAL OF CANCER
    59. Smorenburg, CH; Sparreboom, A; Bontenbal, M; Verweij, J
      Combination chemotherapy of the taxanes and antimetabolites: its use and limitations

      EUROPEAN JOURNAL OF CANCER
    60. Bellmunt, J; de Wit, R; Albanell, J; Baselga, J
      A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer

      EUROPEAN JOURNAL OF CANCER
    61. Caroli-Bosc, FX; Van Laethem, JL; Michel, P; Gay, F; Hendlisz, A; Forget, F; Bleiberg, H
      A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas

      EUROPEAN JOURNAL OF CANCER
    62. Levine, AM; Tulpule, A
      Clinical aspects and management of AIDS-related Kaposi's sarcoma

      EUROPEAN JOURNAL OF CANCER
    63. Garattini, S; La Vecchia, C
      Perspectives in cancer chemotherapy

      EUROPEAN JOURNAL OF CANCER
    64. Giaccone, G
      State of the art in systemic treatment of lung cancer

      EUROPEAN JOURNAL OF CANCER
    65. Sternberg, CN
      Systemic treatment and new developments in advanced prostate cancer

      EUROPEAN JOURNAL OF CANCER
    66. Rougier, P
      Palliative and adjuvant chemotherapy in colorectal cancer

      EUROPEAN JOURNAL OF CANCER
    67. Takeda, Y; Yoshizaki, I; Nonaka, Y; Yanagie, H; Matsuzawa, A; Eriguchi, M
      Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo

      ANTI-CANCER DRUGS
    68. Ong, SYK; Clarke, SJ; Bishop, J; Dodds, HM; Rivory, LP
      Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

      ANTI-CANCER DRUGS
    69. Caponigro, F; Avallone, A; Budillon, A; Comella, P; Comella, G
      Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy

      ANTI-CANCER DRUGS
    70. Li, N; van Agthoven, M; Willemse, PHB; Uyl-de Groot, CA
      A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer

      ANTI-CANCER DRUGS
    71. Chen, JS; Lin, YC; Jan, YY; Liau, CT
      Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas

      ANTI-CANCER DRUGS
    72. Thurnher, D; Kornfehl, J; Burian, M; Gedlicka, C; Selzer, E; Quint, C; Neuchrist, C; Kornek, GV
      Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

      ANTI-CANCER DRUGS
    73. Locker, GJ; Wenzel, C; Schmidinger, M; Gnant, MFX; Marosi, C; Jakesz, R; Zielinski, CC; Steger, GG
      Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancerpatients

      ANTI-CANCER DRUGS
    74. Czuczman, MS
      Combination chemotherapy and rituximab

      ANTI-CANCER DRUGS
    75. Small, EJ
      Docetaxel in prostate cancer

      ANTI-CANCER DRUGS
    76. Posner, MR
      Docetaxel in squamous cell cancer of the head and neck

      ANTI-CANCER DRUGS
    77. Yang, LM; Ostrowski, J; Reczek, P; Brown, P
      The retinoic acid receptor antagonist, BMS453, inhibits normal breast cellgrowth by inducing active TGF beta and causing cell cycle arrest

      ONCOGENE
    78. Vassilomanolakis, M; Koumakis, G; Barbounis, V; Orphanos, G; Efremidis, A
      Prevention of vinorelbine phlebitis with cimetidine - A two-step design study

      SUPPORTIVE CARE IN CANCER
    79. Kern, W; Schleyer, E; Braess, J; Wittmer, E; Ohnesorge, J; Unterhalt, M; Wormann, B; Buchner, T; Hiddemann, W
      Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone [FIS-HAM] salvage therapy in highly resistant acuteleukemias

      ANNALS OF HEMATOLOGY
    80. Harvey, ML; Illidge, T; Johnson, P
      Antibodies in the treatment of lymphoma

      CLINICAL ONCOLOGY
    81. Leonetti, C; Biroccio, A; Benassi, B; Stringaro, A; Stoppacciaro, A; Semple, SC; Zupi, G
      Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

      CANCER GENE THERAPY
    82. Yamada, Y; Shirao, K; Ohtsu, A; Boku, N; Hyodo, I; Saitoh, H; Miyata, Y; Taguchi, T
      Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

      ANNALS OF ONCOLOGY
    83. Younes, A; Preti, HA; Hagemeister, FB; McLaughlin, P; Romaguera, JE; Rodriguez, MA; Samuels, BI; Palmer, JL; Cabanillas, F
      Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    84. Shannon, C; Crombie, C; Brooks, A; Lau, H; Drummond, M; Gurney, H
      Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features

      ANNALS OF ONCOLOGY
    85. Gebbia, V; Testa, A; Borsellino, N; Ferrera, P; Tirrito, M; Palmeri, S
      Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: A new highly active chemotherapeutic regimen

      ANNALS OF ONCOLOGY
    86. Vansteenkiste, J; Gatzemeier, U; Manegold, C; Hanauske, A; Weynants, P; Bosquee, L; Blatter, J; Mansouri, K; von Pawel, J
      Gemcitabine plus etoposide in chemonaive extensive disease small-cell lungcancer: A multi-centre phase II study

      ANNALS OF ONCOLOGY
    87. Dumontet, C
      What can we expect from liposomal drugs?

      ANNALS OF ONCOLOGY
    88. Steele, JPC; O'Doherty, CA; Shamash, J; Evans, MT; Gower, NH; Tischkowitz, MD; Rudd, RM
      Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma

      ANNALS OF ONCOLOGY
    89. Sanz-Altamira, PM; O'Reilly, E; Stuart, KE; Raeburn, L; Steger, C; Kemeny, NE; Saltz, LB
      A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma

      ANNALS OF ONCOLOGY
    90. Carlini, P; Frassoldati, A; De Marco, S; Casali, A; Ruggeri, EM; Nardi, M; Papaldo, P; Fabi, A; Paoloni, F; Cognetti, F
      Formestane, a steroidal aromatase inhibitor after failure of non-steroidalaromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?

      ANNALS OF ONCOLOGY
    91. Matsumoto, M; Takeda, Y; Maki, H; Hojo, K; Wada, T; Nishitani, Y; Maekawa, R; Yoshioka, T
      Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer

      JAPANESE JOURNAL OF CANCER RESEARCH
    92. Proctor, SJ; Taylor, PRA; Angus, B; Wood, K; Lennard, AL; Lucraft, H; Carey, PJ; Stark, A; Iqbal, A; Haynes, A; Russel, N; Leonard, RCF; Culligan, D; Conn, J; Jackson, GH
      High-dose ifosfamide in combination with etoposide and epirubicin (IVE) inthe treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy

      EUROPEAN JOURNAL OF HAEMATOLOGY
    93. Reiser, M; Bredenfeld, H; Engert, A; Diehl, V
      The role of ifosfamide in the treatment of relapsed and refractory lymphoma

      EUROPEAN JOURNAL OF HAEMATOLOGY
    94. Vaughn, DJ; Malkowicz, SB
      Recent developments in chemotherapy for bladder cancer

      ONCOLOGY-NEW YORK
    95. Dreicer, R
      Recent developments in chemotherapy for bladder cancer - The Vaughn/Malkowicz article reviewed

      ONCOLOGY-NEW YORK
    96. Hamilton, A; Muggia, F
      Estramustine potentiates taxane in prostate and refractory breast cancers

      ONCOLOGY-NEW YORK
    97. Curran, WJ; Choy, H
      Optimizing chemoradiation in locally advanced non-small-cell lung cancer

      ONCOLOGY-NEW YORK
    98. O'Reilly, EM; Ilson, DH
      Cisplatin and irinotecan in upper gastrointestinal malignancies

      ONCOLOGY-NEW YORK
    99. Lima, CMSR; Sherman, CA; Brescia, FJ; Brunson, CY; Green, MR
      Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer

      ONCOLOGY-NEW YORK
    100. Vogel, CL
      Systemic therapy for older women with breast cancer - The Kimmick/Muss article reviewed

      ONCOLOGY-NEW YORK


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 04:16:50